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The bioactive and anti-inflammatory role of human milk components has been recognized; active milk components include
soluble forms of Toll-like receptors (TLRs). Preterm babies are more susceptible to infections and may succumb to
necrotizing enterocolitis (NEC), a gastrointestinal disease which is exacerbated by an excessive inflammatory response after
TLR activation. Here, we investigated the presence of Toll-like receptors TLR1/2/4/6 in colostrum and mature milk of
women who delivered before (preterm) or after (term) 37 weeks of gestational age, integrating classical immune-related
techniques with proteomic LC-MS/MS analysis. We have detected immunoreactivity for TLRs mostly in preterm samples,
even for TLR1 and TLR6, until now not described in human milk. We demonstrated the presence of only TLR2 in the milk
fat globule membrane, while the immunoreactivity of TLR1/4/6 was ascribed to crossreaction with some interesting milk
proteins sharing leucine-rich repeat domains. These results will provide new insights into the definition of the role of TLRs
in intestinal immune regulation of the newborns.
1. Introduction
Milk is the first food of mammals, providing them nutrients
but also protection via immunoglobulins and other
immune-related molecules. Milk composition is extremely
dynamic, changing its content in nutrient and bioactive fac-
tors through the lactation stages (colostrum-transition-
mature milk) in order to fulfil the growth needs of the
newborn [1]. Milk proteins are classified as caseins, whey
proteins, and milk fat globule membrane (MFGM) proteins
derived from the apical membrane of the milk-producing
epithelial cells. The most abundant proteins are contained
in whey and casein fractions, while MFGM proteins repre-
sent a minor part (2-4%) of the milk total protein content
[2]. However, minor proteins include nonnutrient bioactive
factors involved in organism development and immune sys-
tem maturation. The benefits of human breast milk for
human infants, in diminishing mortality and protecting
against specific infections during the period of breastfeeding,
are well documented ([1] and references therein). Anyway,
the contribution of human milk molecules to the develop-
ment of the newborn’s innate and adaptive immune function
is still a matter of study. Toll-like receptors (TLRs) are trans-
membrane glycoproteins, involved in the innate immune
response, which recognize conserved molecular structures.
TLRs are composed of an extracellular domain with
leucine-rich repeats (LRRs), a single-path transmembrane
domain, and an intracellular domain called TIR (Toll/IL-1
resistance). The ectodomain is involved in the recognition
of ligands, which induce the dimerization of the intracellular
domain. TLR2 forms heterodimers with TLR1 and TLR6 and
recognizes the broadest range of pathogen-associated
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molecular patterns (PAMPs) among TLRs, including diacy-
lated and triacylated bacterial lipopeptides and glycolipids
such as lipoteichoic acid from Gram-positive bacteria and
lipoarabinomannan from mycobacteria. TLR4 requires the
association with Myeloid Differentiation Factor 2 (MD-2), a
soluble protein that associates with the extracellular domain
of TLR4, to recognize the lipopolysaccharides (LPS). TLR
activation starts a signaling cascade which leads to nuclear
translocation of NF-κB and synthesis of proinflammatory
cytokines. Physiologically, TLR signaling is modulated by
negative regulators, possibly including soluble forms of the
receptor itself. This mechanism avoids the perpetuation of
an inflammatory response which could bring irreversible
damage of the organism ([3] and references therein).
Babies born before 37 weeks of gestation are defined as
“preterm” and present a multifactorial syndrome due to their
limited organ development at birth. Preterm babies are more
susceptible to infections and may succumb to necrotizing
enterocolitis (NEC), a gastrointestinal disease which is exac-
erbated by an excessive inflammatory response after TLR
activation. In this study, we have investigated the presence
of TLR1/2/4/6 in breast milk, using both immunodetection
techniques and proteomic LC-MS/MS analysis. It has been
reported that immunochemical methods applied to a com-
plex substrate such as milk are of concern due to crossreactiv-
ity or nonspecific antibody recognition [4]. Until now,
soluble forms of TLR2 were immunodetected in breast milk
such as 6 isoforms from 20 to 85 kDa [5]; sTLR2 can modu-
late TLR2 signaling and suppress inflammation [6]. We
investigated if it is possible to detect membrane-bound and
soluble forms of TLRs by immunoblotting and mass
spectrometry. Deeper knowledge of anti-inflammatory mole-
cules, like soluble forms of TLRs (or those present in
MFGM), in human milk and their mode of action may help
in the development of strategies to prevent infections in pre-
mature newborns.
2. Materials and Methods
2.1. Human Milk Samples. In this study, we investigated the
presence of immune-related proteins such as TLRs in colos-
trum (0) and mature milk (2) of women who delivered before
(preterm) or after (term) 37 weeks of gestation. Human milk
samples used in this study were provided by Azienda Ospe-
daliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, Ales-
sandria, and the Milk Bank of Ospedale Sant’Andrea,
Vercelli, Italy. The samples (5-10mL) were not pooled, in
order to keep a trace of biological variability, added with a
protease inhibitor cocktail (cOmplete, Mini; Roche), ali-
quoted in 1.5mL tubes, and stored at -80°C until use.
2.2. Milk Fractionation. Milk aliquots were centrifuged at
2000 × g for 30min at 10°C (Fresco 21, Heraeus), and the
subsequent two fractions (milk fat globule membranes
(MFGMs) and skimmed milk) were analyzed separately.
The floating MFGM fraction was prepared as described in
[7], transferred to a new tube, and washed three times with
NaCl 0.9%, followed by a centrifugation step (3000 × g,
30min, 10°C). MFGM proteins were solubilised from mem-
branes after 1-hour incubation at room temperature in urea
7M, thiourea 2M, CHAPS 4%, and DTT 100mM, then cen-
trifuged at 10000 × g for 15min at 10°C, and the soluble frac-
tion was stored at −20°C until use. The liquid fraction with
high protein content, termed skimmed milk, was carefully
recovered in order to avoid contamination from other frac-
tions and stored at -20°C until use.
Protein concentration of each fraction was quantified by
the method of Bradford [8] at 595nm with a Spark 10M
microplate reader (Tecan). BSA was used as the protein stan-
dard. The method was optimized for absorbance readings on
a 96-well microplate, mixing 10μL of buffer/sample/standard
dilution with 200μL of Bradford reagent (Serva).
2.3. Immunoreactivity Detection. The fractions of MFGM
and skimmed milk were analyzed by SDS-PAGE and immu-
noblotting against TLR1, TLR2, TLR4, and TLR6. The
immunoreactivity to β-actin was tested as the internal refer-
ence in the same samples. TLR-reactive profiles of preterm
and term samples were compared by semiquantitative analy-
sis. Skimmed milk and MFGM fractions were also incubated
with anti-TLR antibodies absorbed in a multiwell plate, using
a modified ELISA. After removal of the liquid, proteins inter-
acting with the antibody were eluted and recovered. Immu-
noreactive bands excised from membranes and/or the
corresponding SDS-PAGE bands and eluted fractions from
the ELISA were digested with trypsin and analyzed by LC-
MS/MS using a DDA approach.
2.3.1. SDS-PAGE. Proteins from skimmed milk and MFGMs
were analyzed by SDS-PAGE. The samples (20μg) were
mixed with an equal volume of Laemmli reducing sample
buffer and boiled. Skimmed milk proteins were separated
on a 12.5% polyacrylamide gel, while MFGM proteins were
separated on a 10% gel. A molecular weight protein standard
was also loaded (Precision Plus Protein™ Dual Color Stan-
dards, Bio-Rad, CA, USA). The gels were run in a Mini Pro-
tein Tetra System (Bio-Rad, CA, USA) at 100-120V. The gels
were run in duplicate: one was subjected to Coomassie stain-
ing and the other was used for Western blotting. In the first
case, the gels were fixed in 40%methanol and 10% acetic acid
and stained overnight with Blue Silver [9]. After destaining,
the gel images were acquired with a GS-900 densitometer
(Bio-Rad, CA, USA).
2.3.2. Western Blot Analysis of TLR1, TLR2, TLR4, and TLR6.
After SDS-electrophoresis, proteins were transferred onto a
polyvinylidene fluoride (PVDF) membrane in a Mini
Trans-Blot cell (Bio-Rad, CA, USA) at a constant voltage of
100V on ice for about 90min. The membranes were incu-
bated for one hour at room temperature with a blocking
solution of PBS/BSA 5%+NaN3, then washed for 5min in
Tris-buffered saline (TBS: 150mM NaCl, 10mM Tris-HCl
(pH7.4)), to remove the exceeding BSA. Multiple replicates
were run in order to probe different antibodies on the same
sample, as reported in Table 1: anti-TLR1 (STJ25862, St
John’s Laboratory), anti-TLR2, anti-TLR4 (sc-10739, sc-
10741, Santa Cruz Biotechnology, Inc.), and anti-TLR6
(PRS3653, Sigma-Aldrich Inc., St. Louis, MO, USA). Each
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membrane was split into two identical parts, containing the
same samples, and one half was probed with an anti-β-actin
antibody (20536-1-AP, Proteintech). The membranes were
incubated overnight at 4°C with a primary antibody, then
washed once with Tris-buffered saline-Tween (TBST:
150mM NaCl, 10mM Tris-HCl, and 0.1% Tween 20) for
15min, followed by three washes with TBS (10min). The
membranes were then incubated with an alkaline phospha-
tase- (AP-) conjugated secondary antibody (1 : 3000 in
TBS) (Sigma-Aldrich Inc., St. Louis, MO, USA) at room
temperature for 1 hour. The membranes were then washed
once in TBST for 15min and 4 times in TBST for 5min
and left in AP buffer (100mM Tris-HCl (pH9.5), 100mM
NaCl, and 5mM MgCl2) for 5min. The signals were
detected with BCIP/NBT (5-bromo-4-chloro-3′-indolyl-
phosphate p-toluidine salt/nitro blue tetrazolium chloride,
Sigma-Aldrich Inc., St. Louis, MO, USA), the membrane
images were acquired with a GS-900 densitometer (Bio-Rad,
CA, USA), and band intensities were measured with Image
Lab Software (5.2.1 version, Bio-Rad, CA, USA) and normal-
ized to the expression of β-actin for semiquantitative analysis.
2.3.3. Modified ELISA of Skimmed Milk. In order to identify
soluble components of skimmed milk bound to anti-
TLR1/TLR2/TLR4/TLR6 Abs, colostral skimmed fractions
from healthy preterm donors were analyzed with a modified
ELISA as described in [10]. An ELISA flat-bottomed 96-well
microplate (Pure Grade™, BRAND, Wertheim, Germany)
was coated with 200μL/well of the antibody solution in coat-
ing buffer (0.05M sodium carbonate-bicarbonate (pH9.8)).
The plates were incubated for 4 h at 37°C and washed with
TBST. Residual binding sites were blocked with 200μL/well
of 1% BSA and washed in TBST. Samples in TBST were
added and left overnight at 4°C. After a wash with TBST,
100μL of elution buffer (0.1M Glycin-HCl (pH2.7)) were
added and left for 30min. Finally, the eluate was collected
and neutralized with ammonium bicarbonate 0.1M and
immediately submitted to trypsin digestion.
2.4. Trypsin Digestion of Proteins. Before mass spectrometry
analysis, protein bands separated on SDS-PAGE, immunore-
active bands detected on PVDF membranes, and eluted frac-
tions from the modified ELISA were submitted to trypsin
digestion. Proteins from SDS-gels were in-gel digested as
described in [11] with a few modifications. Briefly, the protein
bands corresponding to the apparent MW of anti-TLR1/2/4/6
immunoreactive bands were excised from Coomassie-stained
gels, destained overnight with 50% methanol and 5% acetic
acid. The gel pieces were subjected to a series of shrinking
steps in acetonitrile, followed by rehydration with 100mM
ammonium bicarbonate (NH4HCO3). Proteins were then
reduced with 10mM dithiothreitol (DTT) in 100mM
NH4HCO3 for 30 minutes at room temperature and alkylated
in the dark with 100mM iodoacetamide in 100mM
NH4HCO3 at room temperature for 30 minutes. The solution
was removed and bands were rinsed in 100mM NH4HCO3
for 5 minutes. After the final rehydrating step, gel bands were
dried in Concentrator Plus (Eppendorf, Germany). Trypsin
(Sequencing Grade, Roche, Germany) was reconstituted and
added to gel pieces. The digestion was performed overnight
at 37°C. The supernatant was collected in a new vial, and
peptides were extracted twice in 50% ACN/0.1% formic
acid (FA) for 10min with an ultrasonic bath. The superna-
tants were pooled, dried, and stored at −20°C until mass
spectrometry (MS) analysis.
Immunoreactive protein bands on PVDF membranes
were excised, thoroughly washed with HPLC water, then
washed once with 50mM NH4HCO3, and submitted to
reducing-alkylating steps as described for in-gel digestion.
After two washes in 50mM NH4HCO3, protein bands were
covered with trypsin solution and incubated overnight at
37°C. Trypsin-digested peptides were collected as described
above. In the case of fainter bands, 4-5 replicates of the same
band were digested and pooled in order to increase the
amount of protein to be analyzed.
Eluates from the modified ELISA were reduced, alky-
lated, covered with trypsin solution as described above, and
incubated overnight at 37°C. The digested samples were
finally dried in Concentrator Plus (Eppendorf, Germany)
and stored at -20°C until mass spectrometry analyses.
2.5. Mass Spectrometry Characterization. The peptide digests
were desalted on the Discovery® DSC-18 solid phase extrac-
tion (SPE) 96-well plate (25mg/well) (Sigma-Aldrich Inc., St.
Table 1: List of antibodies used in this study.
Antibody Source Producer Dilution
Anti-TLR1
Polyclonal rabbit antibody, directed against a
recombinant peptide from human TLR1 (STJ25862)
St John’s Laboratory 1 : 500
Anti-TLR2
Polyclonal rabbit antibody (H-175), directed
against aa 180-354 of human TLR2 (sc-10739)
Santa Cruz Biotechnology, Inc. 1 : 500
Anti-TLR4
Polyclonal rabbit antibody (H-80), directed
against aa 242-321 of human TLR4 (sc-10741)
Santa Cruz Biotechnology, Inc. 1 : 500
Anti-TLR6
Polyclonal rabbit antibody directed against a
peptide of 13 aa near the central part of
human TLR6 (PRS3653)
Sigma-Aldrich 1 : 1000
Anti-β-actin Polyclonal rabbit antibody (20536-1-AP) Proteintech 1 : 2000
Anti-rabbit-AP
Polyclonal goat anti-rabbit antibody conjugated
with alkaline phosphatase (A3687)
Sigma-Aldrich 1 : 3000
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Louis, MO, USA) prior to the mass spectrometry analysis.
The LC-MS/MS analyses were performed with a micro-LC
Eksigent Technologies (Dublin, USA) system that included
a micro LC200 Eksigent pump with flow module 5-50μL
and a programmable autosampler CTC PAL with a Peltier
unit (1.0-45.0°C). The stationary phase was a Halo Fused
C18 column (0:5 × 100mm, 2.7μm; Eksigent Technologies,
Dublin, USA). The mobile phase was a mixture of 0.1%
(v/v) formic acid in water (A) and 0.1% (v/v) formic acid
in acetonitrile (B), eluting at a flow rate of 15.0μLmin-1
and at an increasing concentration of solvent B from 2%
to 40% in 30 minutes. The injection volume was 4.0μL.
The oven temperature was set at 40°C.
The LC system was interfaced with a 5600+ Triple-
TOF™ system (AB Sciex, Concord, Canada) equipped with
DuoSpray™ Ion Source and CDS (Calibrant Delivery Sys-
tem). The mass spectrometer worked in a data-dependent
acquisition mode (DDA). Peptide profiling was performed
using a mass range of 100–1300Da (TOF scan with an accu-
mulation time of 100.0ms), followed by a MS/MS product
ion scan from 200 to 1250Da (accumulation time of
5.0ms) with the abundance threshold set at 30 cps (35 candi-
date ions can be monitored per cycle). The ion source
parameters in an electrospray positive mode were set as
follows: curtain gas (N2) at 25 psig, nebulizer gases GAS1
at 25 psig and GAS2 at 20 psig, ionspray floating voltage
(ISFV) at 5000V, source temperature at 450°C, and
declustering potential at 25V.
2.6. Protein Database Search. The DDA files were searched
using Mascot v. 2.4 (Matrix Science Inc., Boston, USA).
Trypsin as a digestion enzyme was specified with 2 missed
cleavages. The instrument was set to ESI-QUAD-TOF, and
the following modifications were specified for the search: car-
bamidomethyl cysteines as fixed modification and oxidized
methionine as variable modification. A search tolerance of
50 ppm was specified for the peptide mass tolerance, and
0.1Da for the MS/MS tolerance. The charges of the peptides
to search for were set to 2+, 3+, and 4+, and the search was set
on monoisotopic mass. The UniProt Swiss-Prot human
unreviewed database (version 2017.06.21, containing 43234
sequence entries) was used. Only proteins with at least two
peptides with individual ion scores > 20 were considered for
identification purposes.
2.7. TLR1/2/4/6 Sequence Alignment. Sequences of
TLR1/2/4/6 mature forms were aligned with Clustal Omega
[12] in order to evaluate their homology degree. FASTA
sequences of TLR1, TLR2, TLR4, and TLR6 used for the
alignment are reported in Figure 1. The alignment of mature
TLR1 with TLR6 revealed an identity percentage of 69.4%.
TLR4 has the lowest identity compared with the other TLRs
(23-25%). TLR2 shows a higher percentage of identity with
TLR1 and TLR6 (30%) than with TLR4 (22.7%).
3. Results and Discussion
3.1. SDS-PAGE Protein Profile. The protein profile of
MFGM and skimmed milk (SM) fractions after SDS-
PAGE is shown in Figures 2 and 3, respectively. Milk sam-
ples obtained from healthy donors who delivered at term
(T) or preterm (PT) and two milk stages (colostrum and
mature milk) were analyzed.
MFGM and skimmed milk fractions show a different and
characteristic protein profile. Though protein profiles of
samples from the same milk fraction are quite similar, it is
possible to observe little individual variability, with protein
bands of different intensities. The most notable difference is
observed between samples of different gestational ages; the
colostrum of donors who delivered at term shows the lack
of a band related to casein, with regard to preterm samples.
The absence of casein in the colostrum of early production
is reported in literature [13, 14]. In our case, the difference
between term and preterm colostrum could be related to a
delayed collection of milk (between the 3rd and 5th day of
lactation) in mothers who delivered at preterm.
3.2. Analysis of TLR Expression in MFGMs. Immunoblots of
MFGMs obtained from colostrum and mature milk samples
using anti-TLR1/TLR2/TLR4/TLR6 are shown in Figures 4
and 5, respectively. Colostrum showed immunoreactivity
versus anti-TLR1 at 150 kDa and 100 kDa, especially in
preterm samples. Similarly, anti-TLR2 reactivity is more
evident in preterm colostrum, with the appearance of a
single band at 100 kDa. We could not observe any reactive
band after anti-TLR4 Ab incubation (see also Supplemen-
tary Figure S1 and Figure S3). Finally, the incubation with
anti-TLR6 Ab determined the appearance of a prevalent
band at 80-85 kDa and a series of bands with lower
molecular weight. Among these, a 50 kDa band is especially
evident in preterm milk. The presence of bands around 80-
100 kDa is in accordance with the molecular weight of the
analyzed TLRs.
Immunoblot analysis of mature milk MFGM proteins
confirmed anti-TLR1 reactivity in both term and preterm
samples at 150 kDa, but if compared with colostrum, the
band at 100 kDa disappeared while a new band more evi-
dent in preterm samples came out at 30 kDa. Two bands
detectable in all samples appeared at 100 and 80 kDa after
incubation with an anti-TLR2 antibody, while anti-TLR4
reactivity was observed at 75 kDa (see also Supplementary
Figure S2 and Figure S4). All samples tested showed two
prevalent bands at 80 kDa and at 50 kDa, after anti-TLR6
antibody incubation.
Semiquantitative analysis of immunoreactive bands in
MFGMs (data not shown), obtained after actin standardiza-
tion, confirmed the differences observed between term and
preterm mainly in colostral samples. Immunoblotting results
show changes in the amount of actin; anyway, we used actin
normalization assuming that the presence of actin in milk
originates from cell residues, since actin is not a typical milk
secreted protein and could represent proportionally the
amount of cells from which TLRs are derived.
Colostrum of preterm donors shows higher immunore-
activity to anti-TLR1 Ab than that of term women, with
two intense bands at 150 and 100 kDa. The band at 100 kDa
disappeared in mature milk, while a new band at 30 kDa
appeared, with higher intensity in preterm samples.
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Concerning colostrum, we could observe anti-TLR2 reactiv-
ity only in preterm samples, while two reactive bands at
100 and 80 kDa were detectable in each sample of mature
milk tested. Interestingly, we could not observe any anti-
TLR4 reactivity in colostral samples, while a band appeared
in each sample of mature milk. Preterm colostral samples
showed higher reactivity, at 75 and 50 kDa, to anti-TLR6
Ab too. The intensity values of these bands declined in
mature milk.
3.3. Analysis of TLR Expression in Skimmed Milk. Immuno-
blots of skimmed fractions from colostrum and mature milk
samples using the anti-TLR1/TLR2/TLR4/TLR6 antibodies
are shown in Figures 6 and 7, respectively. Anti-β-actin reac-
tivity of the same samples was used as an internal standard.
Concerning colostrum skimmed fraction, two bands
around 75 kDa appeared after anti-TLR1 Ab incubation,
but if compared with MFGM fraction, no bands at 150-
100 kDa were observed. Anti-TLR2 and anti-TLR4 Abs
determined the appearance of two bands at 75 and 50 kDa
(Supplementary Figure S5 and Figure S7). However, these
bands were considered aspecific since the same profile was
observed in samples probed with anti-β-actin Ab. An
additional band at 25 kDa was observed after anti-TLR4 Ab
incubation. The immunoreactive profile after anti-TLR6 Ab
incubation is quite similar, with the appearance of high
MW bands (250 kDa, 150 kDa), a most intense band
between 100 and 75 kDa (the only one clearly observed in
4PT), and minor bands at 50 kDa, 37 kDa, and 25 kDa.
Concerning the skimmed fraction of mature milk, the
immunoreactive profile observed after anti-TLR1/2/4/6
incubation is shown in Figure 7.
A 150 kDa band appeared in all samples except in 7 T
after anti-TLR1 Ab incubation. As observed in colostrum,
Figure 1: Sequences of TLR1, TLR2, TLR4, and TLR6 mature forms, preceded by UniProt identifier, initial and final amino acid number, and
estimated molecular weight.
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we did not detect signals relative to TLR2 and TLR4 but only
aspecific bands at 75 and 50 kDa (Supplementary Figure S6
and Figure S8). Reactivity to anti-TLR6 Ab was similar to
that observed for the skimmed fraction of colostrum. The
main bands were observed between 75 and 100 kDa.
Immunoreactive bands against anti-TLR1 and anti-TLR4
Abs showed higher intensity in preterm than in term sam-
ples of colostrum. This trend is no more evident in mature
samples, where these bands disappeared and a clear band
at 150 kDa appeared only after anti-TLR1 Ab incubation.
Concerning anti-TLR6 immunoreactivity, bands of higher
intensity were observed in colostrum than in mature
skimmed milk. Again, colostrum preterm samples revealed
higher intensity bands at 75-100 kDa. This trend is no
more evident in lower MW bands of both colostrum and
mature skimmed milk.
The observed differences between preterm and term
samples are supported by evidences reported in literature.
The concentration of total protein is higher in preterm milk
[15], and their expression is differently regulated. In a study
on human skimmed milk [16], 28 proteins with higher
expression levels and 27 proteins with lower levels were
found in preterm milk compared to term milk.
Concerning TLRs, the presence of bands with apparent
molecular weight lower than that of TLR mature forms
(which is estimated between 87 kDa and 93 kDa considering
the amino acidic sequence only) could be due to posttransla-
tional modifications, with the production of truncated forms.
1 T 2 PT 3 T 4 PT 5 T 6 PT 7 T 8 PT
Colostrum Mature
250
100
150
75
37
50
20
25
Xanthine
dehydrogenase/
oxidase
Lactoferrin,
butyrophilin
Perilipin-2
Lactadherin
Figure 2: Electrophoretic profile of MFGM proteins in colostrum and mature milk. Gestational age is indicated as “T” (term) or “PT”
(preterm). Each number refers to a different milk sample.
Colostrum Mature
250
150
100
75
50
25
20
37
1 T 2 PT 3 T 4 PT 5 T 6 PT 7 T 8 PT
Β-casein
Lactoferrin
Ig heavy chains,
serum albumin
Ig light chains
Figure 3: Electrophoretic profile of skimmed milk proteins in colostrum and mature milk. Gestational age is indicated as “T” (term) or “PT”
(preterm). Each number refers to a different milk sample.
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In literature, there is some evidence of TLR2 and TLR4 solu-
ble forms (sTLRs) revealed by Western blot analysis of bio-
logical samples such as saliva, amniotic fluid, plasma, and
milk [5, 17, 18]. To our knowledge, the presence of soluble
forms of TLR1 and TLR6 has never been reported. Immuno-
blot analysis of normal unstimulated whole saliva (UWS)
revealed three sTLR2 polypeptides of 54, 40, and 30 kDa
and four sTLR4 polypeptides of 90, 78, 54, and 44 kDa [17].
Two polypeptides (42 and 30 kDa), corresponding to the
extracellular domain of the full-length TLR2 receptor
(98 kDa), were found in the human amniotic fluid, where
the 42 kDa isoform is the main sTLR2 released. In this com-
partment, sTLR2 forms were found to be constitutively
expressed, but their expression level is regulated by gesta-
tional age, with high sTLR2 expression levels observed until
the 37th week of gestation and decreasing levels in women
who delivered at term [18]. LeBouder and colleagues [5] were
the first to report the presence of soluble forms of TLR2 in
human plasma and milk, where they observed up to six poly-
peptide bands of 83, 70, 66, 40, 38, and 25 kDa. Another
study [19] reported variations to this pattern in breast milk,
in terms of number and intensity of bands, with the absence
of 70 and 40 kDa bands and the appearance of a 130 kDa
band, probably due to sample variability and the type of anti-
body tested. In fact, the polyclonal (p) Ab used was found to
be specific for the 83 and 38 kDa bands, whereas the mono-
clonal (m) Abs tested revealed two bands of 83 and 26 kDa.
Moreover, pAb detected the presence of commercially avail-
able recombinant sTLR2 produced in mouse myeloma cell
lines, while anti-TLR2 mAbs were unable to detect the
recombinant protein. Our results differ from the previous
reports, since we observed only a 25 kDa band after anti-
TLR4 Ab incubation in the skimmed fraction of colostrum.
The difference could be due to a number of reasons, such as
the choice of antibody, which could recognize an N-term or
Anti-TLR6
Anti 𝛽-actin
250 
43 
150
100 
75 
50 
37 
25 
43 
Anti-TLR4
43 Anti 𝛽-actin
100
150 Anti-TLR1
kDa 1 T 3 T2 PT 4 PT
1 T 3 T2 PT 4 PT
1 T 3 T2 PT 4 PT
1 T 3 T2 PT 4 PT
Anti 𝛽-actin
100
Anti-TLR2
43 Anti 𝛽-actin
100
kDa
kDa
kDa
Figure 4: Immunoblot of TLR1/2/4/6 in MFGMs of colostrum.
Gestational age is indicated as “T” (term) or “PT” (preterm). Each
number refers to a different milk sample. Standard molecular
weights are indicated on the left. Each box shows the blot
reactivity to a specific anti-TLR antibody and, on the lower side,
the same blot incubated with an anti-β-actin antibody.
Anti-TLR2
43 Anti 𝛽-actin
100
Anti-TLR1
kDa 5 T 6 PT 7 T 8 PT
5 T 6 PT 7 T 8 PT
5 T 6 PT 7 T 8 PT
5 T 6 PT 7 T 8 PT
43 Anti 𝛽-actin
150
30
Anti-TLR4
43 Anti 𝛽-actin
75
Anti-TLR6
43 Anti 𝛽-actin
100
75
50
37
kDa
kDa
kDa
Figure 5: Immunoblot of TLR1/2/4/6 in MFGMs of mature milk.
Gestational age is indicated as “T” (term) or “PT” (preterm). Each
number refers to a different milk sample. Standard molecular
weights are indicated on the left. Each box shows the blot
reactivity to a specific anti-TLR antibody and, on the lower side,
the same blot incubated with an anti-β-actin antibody.
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a C-term region of TLR. The mechanism of sTLR production
is still unclear, but it was suggested that sTLR2 production
does not involve new protein production and is a result of
posttranslational modification, probably starting from the
C-terminal side [5]. The Abs chosen in this study recognize
a central region of the TLR2 and TLR4 ectodomains, but part
of them could be removed during the processing of soluble
forms with the consequent failure of protein binding.
Another possibility could be the time-related amount of sol-
uble forms in milk, since a decline of sTLR2 levels over time
postpartum was reported, with the disappearance of some
soluble forms few days after delivery [5, 19]. Finally, it is
possible that some signals reflect nonspecific binding of the
anti-TLR2 and anti-TLR4 polyclonal Abs to proteins consti-
tutively present in the human milk, as previously stated in
[18]. In the skimmed fraction of milk, we observed two
anti-TLR2/TLR4 immunoreactive bands at 75 and 50 kDa
that were considered aspecific since the same reactive profile
was observed after anti-β-actin Ab incubation.
3.4. Mass Spectrometry Identifications. Mass spectrometry
analysis of immunoreactive bands detected in MFGM and
skimmed milk fractions (Figure 8) led to the identification
of TLR2 and some TLR-related proteins, but the presence
of TLR1/4/6 was not determined (Supplementary Table S1).
In detail, TLR2 was identified in B2, B4, G2, and G11;
antigen CD14 was identified in B6, B11, B12, G12, and
G13; CD36 glycoprotein was identified in G3, G8, G12, S1,
S2, and B8; leucine-rich protein was identified in S3, S4, S5,
G7, and G12; tenascin was identified in S1, S3, S4, S5, S6,
S8, S10, B1, B2, B6, B11, B12, and G12; and zinc alpha
glycoprotein was identified in S3, S4, and S5.
TLR2 was detected by mass spectrometry in the MFGM
fraction only, with peptides of six different sequences. In
order to assess if TLR2 found in the MFGM fraction corre-
sponds to the whole receptor or parts of it, the sequences of
the identified peptides were overlapped to the complete
sequence of TLR2. As shown in Figure 9, MS-identified pep-
tides almost cover the entire sequence of TLR2, with four
peptides belonging to the extracellular domain (SLDLSNNR:
aa 56-63 corresponding to leucine-rich repeat (LRR) 1;
VGNMDTFTK: aa 156-164, LRR 5; TGETLLTLK: aa 404-
413, LRR 14-15; and TLEILDVSNNNLNLFSLNLPQLK: aa
458-480, LRR 17-18), one belonging to the transmembrane
region (GQQVQDVR: aa 572-579, LRRCT), and one belong-
ing to the C-terminal intracellular domain (LFDENNDAAI-
LILLEPIEK: aa 724-742, TIR), confirming the association of
the detected form of TLR2 with the MFG membrane.
Our MS results are supported by studies reporting the
finding of TLR2 in MFGMs but not in serum of milk [2, 20].
Concerning other TLRs, the presence of TLR1/2/3/4/5/6/7/9
was detected at an mRNA level in cells isolated from human
breast milk [21]; however, proteomic studies performed so
far do not report the presence of TLR1 and TLR6 proteins in
MFGM and skimmed fractions of breast milk.
It is interesting to note that our MS analysis of immuno-
reactive bands detected some TLR-related proteins such as
CD14 and CD36 or LRR-containing proteins. Cluster of dif-
ferentiation 14 (CD14) is a pattern recognition receptor with
a bent solenoid structure typical of leucine-rich repeat pro-
teins [22]. It is present in soluble form in the blood or as a
GPI-anchored membrane protein on myeloid cells and
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Figure 6: Immunoblot of TLR1/4/6 in colostral skimmed milk.
Gestational age is indicated as “T” (term) or “PT” (preterm). Each
number refers to a different milk sample. Standard molecular
weights are indicated on the left. Each box shows the blot
reactivity to a specific anti-TLR antibody and, on the lower side,
the same blot incubated with anti-β-actin Ab.
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Figure 7: Immunoblot of TLR1/6 in mature skimmed milk.
Gestational age is indicated as “T” (term) or “PT” (preterm). Each
number refers to a different milk sample. Standard molecular
weights are indicated on the left. Each box shows the blot
reactivity to a specific anti-TLR antibody and, on the lower side,
the same blot incubated with anti-β-actin Ab.
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interacts with TLR2 and TLR4 in ligand recognition [3].
CD14 acts as a coreceptor for TLR2/TLR6 and for
TLR2/TLR1 heterodimers in response to diacylated and tria-
cylated lipopeptides, respectively [23], and belongs to the
lipopolysaccharide (LPS) receptor, a multiprotein complex
containing at least CD14, MD2, and TLR4 [24]. CD36 (clus-
ter of differentiation 36) is a multifunctional glycoprotein
involved in TLR pathways. It acts as a receptor for a broad
range of ligands (proteins and lipids), interacting with multi-
ple receptors and participating in signal transduction. CD36
is involved in TLR2 activation by microbial anionic ligands
such as lipoteichoic acid and TLR4/TLR6 by endogenous
ligands. A model proposed in [25] suggests an interaction
between CD36 and CD14, where CD36 binds to anionic
ligands and transfers them to CD14 which loads them into
TLR2/TLR1 or TLR2/TLR6 heterodimers. In this work, we
identified CD14 in the MFGM fraction only, while other
studies report its presence in the skimmed fraction too [16].
On the contrary, CD36 was detected in both MFGM and
skimmed fractions of milk.
Identified proteins in skimmed milk include zinc α2-
glycoprotein and leucine-rich α-2-glycoprotein. Zinc α2-
glycoprotein (ZAG) is a 40 kDa protein secreted in body
fluids, which stimulates lipid degradation in adipocytes.
The exact function of ZAG in physiological conditions is
still unknown. ZAG shows high sequence homology with
a lipid-mobilizing factor; thus, it is considered an adipo-
kine. However, its structure is similar to that of MHC class
I antigen-presenting molecule indicating that ZAG may
have a role in the immune response [26]. Leucine-rich α2
glycoprotein (LRG1) is a 40 kDa serum protein and the
founding member of the leucine-rich repeat (LRR) family
of proteins. It is involved in neutrophil degranulation, pos-
itive regulation of angiogenesis, and proliferation of endo-
thelial cells [27, 28]. LRG1 can bind to cytochrome c, a
molecule that in the extracellular space is implicated in
the initiation of arthritis via the NF-κB pathway, suggesting
its role as a proinflammatory molecule [29]. LRG1 was found
to mitigate apoptosis in lymphocytes treated with extracellu-
lar cytochrome c [30].
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Figure 8: Representative image of proteins from MFGM (a) and skimmed milk (b) fractions of colostrum (0) and/or mature milk (2) after
SDS-PAGE separation. The name of bands analyzed by mass spectrometry is reported beside each lane. Bands labelled with “B” were digested
from PVDF blots, while “G” bands were digested from polyacrylamide gels. S1 was digested from polyacrylamide gels, and S2, S3, S4, S5, S6,
S7, S8, S9, and S10 were digested from PVDF blots.
Figure 9: Protein sequence of TLR2. The signal peptide is highlighted in green, while identified peptides after mass spectrometry are
highlighted in yellow.
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Leucine-rich repeats and immunoglobulin-like domains
protein 1 (LRIG1) is another LRR-containing protein
found in both MFGM and skimmed fractions of milk.
LRIG1 is a membrane protein with a series of LRRs, three
immunoglobulin-like (Ig-like) domains, one transmembrane
domain, and a cytosolic tail. It is a negative regulator of sig-
naling by receptor tyrosine kinases. LRIG1 interacts with
EGFR/ERBB1, ERBB2, ERBB3, and ERBB4 family receptors
through the LRR and Ig-like extracellular domains [31].
However, its physiological role is still controversial, since
LRIG1 may have low affinity for EGFR and their interac-
tion could take place only with high quantity levels of both
proteins [32].
Finally, tenascin, a glycoprotein of the extracellular
matrix implicated in neuronal and axonal migration during
development, was identified in the MFGM and skimmed
fractions. It contains EGF-like and fibronectin type III
domains and can exist in homoexameric or homotrimeric
forms. Tenascin is involved in various physiological pro-
cesses such as cell adhesion, cellular response to vitamin D
and retinoic acid, extracellular matrix organization, and pos-
itive regulation of cell proliferation.
Its expression is induced by TGF-β1, and it is released
after cell damage of infections. In fact, tenascin quickly reacts
during acute inflammatory response to LPS, through the acti-
vation of TLR4 or integrins, promoting the innate immunity
response with the synthesis of proinflammatory cytokines
[33]. Although its role in the mammary gland and human
breast milk is still unknown, tenascin may be involved in tis-
sue reshaping associated with pregnancy. A different glyco-
sylation pattern of tenascin has been reported in the milk of
preterm with respect to term women. Since tenascin func-
tions depend on adhesion ability with other MEC compo-
nents and membrane receptors, a different glycosylation
profile may change such properties [20]. We could identify
tenascin in the skimmed milk, where probably it is more rep-
resented, as demonstrated by the higher number of peptides
identified, but also in the MFGM fraction. Such observation
is compatible with its role as an extracellular matrix protein,
which could be secreted or associated with the membrane.
The presence of tenascin in the MFGM of milk has previ-
ously been reported, and it shows higher expression levels
in colostrum than in mature milk [34], whereas lower levels
of tenascin were detected in the skimmed milk of preterm
with respect to term women [16].
3.5. MS Analysis of Proteins after the Modified ELISA Test.
Since TLR2 was detected only in MFGM, a further test on
skimmed milk fractions was performed with the modified
ELISA, in order to selectively detect proteins interacting with
the anti-TLRs used in this study. We limited the assay to
colostrum of preterm women, since after Western blotting
analyses, we observed more intense immunoreactive profiles
in these samples. After anti-TLR1 Ab incubation, we detected
lactotransferrin and phosphatidylinositol 4,5-bisphosphate
5-phosphatase A, a protein with two isoforms of 100 and
70 kDa (in the WB, we observed a 75 kDa band). Anti-
TLR2 incubation revealed again the presence of lactotrans-
ferrin and Rho GTPase-activating protein 7 (in the WB, a
75 kDa band was observed). Anti-TLR4 interacted with zinc
α2-glycoprotein and lactotransferrin (in the WB, 25 kDa
was observed) whereas anti-TLR6 Ab incubation with
skimmed milk revealed the presence of lactotransferrin and
β-casein (WB revealed a series of bands at 100-75, 50, 37,
and 25 kDa). The MS of modified ELISA eluates did not
reveal any TLR. Lactotransferrin was detected in all the sam-
ples: this highly abundant protein could have “obscured”
other potential targets, but this event raises the question of
Ab specificity.
4. Conclusions
MFGM fraction from preterm colostrum showed higher
reactivity to anti-TLR1, anti-TLR2, and anti-TLR6 antibod-
ies, compared to that from term samples. In the skimmed
fraction, no immunoreactivity to anti-TLR2 was observed,
whereas bands at low molecular weight appeared after incu-
bation with anti-TLR4 and anti-TLR6 antibodies. LC-
MS/MS analysis of immunoreactive bands confirmed the
presence of the entire membrane receptor TLR2 in the
MFGM of human milk, but not in the skimmed milk. With
regard to TLR1, TLR4, and TLR6, despite the observation
of immunoreactive bands, their presence was not confirmed
after MS analysis. However, it is interesting to note that the
MS analysis of these bands allowed the identification of pro-
teins related to TLRs, because of the presence of LRR
domains in their sequence or their direct interaction with
TLRs. MS analysis of the ELISA fractions did not reveal any
TLR but confirmed proteins identified in immunoreactive
bands. The presence of soluble forms of TLRs in human milk
remains an open question. It is possible that the soluble
forms of TLRs in milk reported in literature, which were
observed only by immunoblot assays, are related to cross-
reactivity events with these proteins. Anyway, the lack of
MS identification for TLR1, TLR4, and TLR6 cannot assure
their total absence in milk, where their concentration may
be inferior to the limit of detection of the instrument and
the DDA method used in this study could have excluded
them. It is clear that TLR2 is surely present in milk, and we
suggest that soluble forms may be ascribed to other milk pro-
teins sharing conformational domains capable of reacting
with and modulating TLR signaling.
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plete Western blot with anti-TLR2 for skimmed colostrum.
Figure S6: complete Western blot with anti-TLR2 for
skimmed mature milk. Figure S7: complete Western blot
with anti-TLR4 for skimmed colostrum. Figure S8: complete
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